Information for patients
We are moving from promise to practice in the clinic.View our clinical trials
About Denintuzumab Mafodotin (SGN-CD19A; 19A)
SGN-CD19A is an antibody-drug conjugate (ADC) targeting CD19, a protein expressed broadly on B-cell malignancies. 19A is comprised of an anti-CD19 monoclonal antibody linked to a synthetic cell-killing agent, monomethyl auristatin F (MMAF). The ADC is designed to be stable in the bloodstream, and to release its cytotoxic agent upon internalization into CD19-expressing tumor cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy while enhancing the antitumor activity.
A phase 2 clinical trial is evaluating 19A in combination with chemotherapy for relapsed diffuse large B-cell lymphoma (DLBCL). A phase 2 trial in frontline DLBCL is planned for 2016.